Business

YL Biologics Limited is a joint venture between Yoshindo Inc. (headquartered in Toyama, Japan) and Lupin Limited (headquartered in Mumbai, India).
We develop biosimilar drugs, gain approval and bring them into market in Japan.

We procure top-level APIs (or active pharmaceutical ingredients) worldwide including from Lupin Limited. All our products are made in Japan with no exception. We are committed to provide high quality, highly credible biosimilar drugs.

Our highly experienced experts in biosimilar development will conduct clinical study both in Japan and abroad.

More drug pipelines are underway.

Development
code
Generic
name
Development
phase
Country/
Region
YLB113 Etanercept biosimilar Approved (March 26, 2019)
Manufacturing and marketing approval transferred to Yoshindo Inc. (May 1, 2020)
Japan
YLB217 Darbepoetin alfa biosimilar In Preparing for NDA Application Japan